These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 35549164)

  • 1. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma.
    Liu D; Cheng Y; Qiao S; Liu M; Ji Q; Zhang BL; Mei QB; Zhou S
    ACS Nano; 2022 May; 16(5):7409-7427. PubMed ID: 35549164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression.
    Zhao W; Yun K
    Exp Cell Res; 2022 Sep; 418(2):113277. PubMed ID: 35810776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells.
    Tsuji S; Nakamura S; Shoda K; Yamada T; Shimazawa M; Nakayama N; Iwama T; Hara H
    J Neurooncol; 2022 Nov; 160(2):375-388. PubMed ID: 36308592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
    Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
    J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
    Xin L; Tan Y; Zhu Y; Cui X; Wang Q; Zhao J; Tian S; Xu C; Xiao M; Hong B; Xu J; Yuan X; Wang C; Kang C; Fang C
    Neuro Oncol; 2023 Nov; 25(11):1976-1988. PubMed ID: 37279651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
    Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A modified nucleoside O6-methyl-2'-deoxyguanosine-5'-triphosphate exhibits anti-glioblastoma activity in a caspase-independent manner.
    Wang ZH; Li J; Liu Q; Qian JC; Li QQ; Wang QY; Zeng LT; Li SJ; Gao X; Pan JX; Gao XF; Wu K; Hu GX; Iwakuma T; Cai JP
    Pharmacol Res; 2024 Jan; 199():106990. PubMed ID: 37984506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
    Lin R; Xu Y; Xie S; Zhang Y; Wang H; Yi GZ; Huang G; Ni B; Song H; Wang Z; Qi ST; Liu Y
    J Neurooncol; 2022 Mar; 157(1):15-26. PubMed ID: 35187626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma.
    Vengoji R; Atri P; Macha MA; Seshacharyulu P; Perumal N; Mallya K; Liu Y; Smith LM; Rachagani S; Mahapatra S; Ponnusamy MP; Jain M; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2021 Oct; 40(1):335. PubMed ID: 34696786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
    Alejo S; Palacios BE; Venkata PP; He Y; Li W; Johnson JD; Chen Y; Jayamohan S; Pratap UP; Clarke K; Zou Y; Lv Y; Weldon K; Viswanadhapalli S; Lai Z; Ye Z; Chen Y; Gilbert AR; Suzuki T; Tekmal RR; Zhao W; Zheng S; Vadlamudi RK; Brenner AJ; Sareddy GR
    Neuro Oncol; 2023 Jul; 25(7):1249-1261. PubMed ID: 36652263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
    Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.
    Zhou J; Tong F; Zhao J; Cui X; Wang Y; Wang G; Kang C; Liu X; Wang Q
    Cancer Biol Med; 2023 Jun; 20(5):385-400. PubMed ID: 37283490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM.
    Liu B; Ji Q; Cheng Y; Liu M; Zhang B; Mei Q; Liu D; Zhou S
    J Nanobiotechnology; 2022 Mar; 20(1):161. PubMed ID: 35351131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A hypoxia-dissociable siRNA nanoplatform for synergistically enhanced chemo-radiotherapy of glioblastoma.
    Xie Y; Lu X; Wang Z; Liu M; Liu L; Wang R; Yang K; Xiao H; Li J; Tang X; Liu H
    Biomater Sci; 2022 Nov; 10(23):6791-6803. PubMed ID: 36314541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
    Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.